Enanta Pharmaceuticals, Inc. - מכפיל EV/Sales ENTA

לוגו של חברה ציבורית Enanta Pharmaceuticals Inc. (ENTA)

The potential for high-cost drugs treating viral pathologies of the liver and lungs defines the market vector for Enanta Pharmaceuticals (ENTA). The current EV/Sales ratio visualizes this trend, where the 3421.59 mark characterizes this parameter. Royalties and small-molecule patents provide stability, while a strong R&D pool is supported by a system of options and bonuses for leading chemists.

ENTA: שווי חברה להכנסות Enanta Pharmaceuticals Inc. 23.11.2025 - 20.11.2026

פילוחי מדדים פיננסיים ומדדי שוק עבור Enanta (ENTA)

- מחיר מניה וקונצנזוס הערכת שווי:
ניתוח ראשוני של החברה:Enanta Pharmaceuticals
מוצר סדרתי של Enanta Pharmaceuticals Inc.

This metric reflects the ratio of the total enterprise value, including debt, to the volume of generated sales. The metric demonstrates how much an investor pays per unit of revenue, excluding the influence of capital structure. The Enterprise Value-to-Revenue (EV/Revenue) ratio dynamics on the GURU.Markets platform allow for an assessment of market expectations regarding growth rates. For Enanta Pharmaceuticals (ENTA), this serves as an indicator of the premium for the patent protection of small molecules. Stable royalty streams make this valuation more predictable, smoothing out the volatility associated with clinical stages.